SBIR Technology Transfer (R43/R44 Clinical Trial Not Allowed) | PA 18 705

Frequently Asked Questions (FAQs): SBIR Technology Transfer (R43/R44, Clinical Trial Not Allowed) - PA 18-705

1) What is the purpose of the SBIR Technology Transfer (R43/R44 Clinical Trial Not Allowed) opportunity (PA 18-705)?

This NIH SBIR funding opportunity is designed to move inventions created inside NIH intramural research laboratories into the private sector for commercial development. The focus is technology transfer: NIH is looking for eligible U.S. Small Business Concerns (SBCs) that can take NIH-owned or NIH-controlled technologies and advance them toward real-world products that benefit public health.

2) What type of funding mechanism is this?

This is an NIH discretionary grant program using the SBIR grant mechanism. The activity codes are R43 and R44, which align with the phased SBIR structure (commonly Phase I for feasibility/proof-of-concept and Phase II for further development).

3) What does "R43/R44" mean in practical terms?

R43 and R44 correspond to the SBIR phases. In general terms, Phase I (often R43) supports feasibility and early proof-of-concept work, and Phase II (often R44) supports continued development and advancement of the technology. The opportunity supports early-stage R&D intended to de-risk and validate an NIH intramural invention for market readiness.

4) Are clinical trials allowed under this FOA?

No. The announcement is explicitly labeled "Clinical Trial Not Allowed," meaning the proposed project scope must not include conducting a clinical trial as defined by NIH policy. Projects can still be clinically relevant, but the funded work must stop short of clinical trial activities.

5) If clinical trials are not allowed, what kinds of R&D activities are a fit?

The FOA is positioned to support translational and commercialization-enabling steps that do not meet NIH's definition of a clinical trial. Examples described or implied by the opportunity include preclinical development, prototyping, assay development, software or device refinement (without clinical trial testing), manufacturing process development, analytical validation, and other steps that prepare an invention for later-stage testing and commercialization.

6) What is distinctive about the licensing arrangement for awardees?

A defining feature is that selection for SBIR funding under this FOA is tied to an NIH license. If an SBC is selected, NIH will provide a royalty-free, non-exclusive patent license agreement for internal research use. The license is limited to (a) the term of the SBIR award and (b) the field of use of the award, meaning it is scoped to the R&D proposed in the funded project.

7) Does the NIH license provided under this FOA automatically grant commercial exclusivity?

No. The license described is royalty-free and non-exclusive for internal research use during the award term and within the award's field of use. The information provided does not indicate that broad commercial exclusivity is included by default.

8) What does "internal research use" mean in the context of this NIH license?

Based on the description, it means the company is granted rights to use NIH-held intellectual property to carry out the specific research and development proposed in the funded SBIR project. The rights are aligned with the SBIR-supported research plan and timeframe rather than unrestricted commercial use.

9) Who is eligible to apply?

Eligibility is focused on U.S. small businesses that meet SBIR rules (Small Business Concerns, or SBCs). The applicant organization must be an eligible U.S. small business.

10) Are foreign (non-U.S.) entities eligible to apply?

No. The FOA states that non-domestic (non-U.S.) entities (foreign institutions) are not eligible to apply.

11) Are non-domestic components of U.S. organizations eligible?

No. The FOA states that non-domestic components of U.S. organizations are not eligible to apply.

12) Are any foreign activities allowed at all?

The FOA indicates that foreign components (as defined in the NIH Grants Policy Statement) may be allowed in some cases. This suggests limited, well-justified parts of the work might be performed outside the U.S. if they meet NIH policy requirements and are specifically permitted, while the applicant organization itself must still be an eligible U.S. SBC.

13) What is NIH trying to achieve through this program beyond basic research?

The program emphasizes translation and commercialization readiness. The goal is to enable a small business to de-risk, validate, and advance an NIH intramural invention toward market readiness and eventual public health benefit, while staying within the SBIR framework and excluding clinical trials.

14) What kinds of technologies can be supported?

The opportunity targets NIH-owned or NIH-controlled technologies originating from NIH intramural research laboratories. Because multiple NIH institutes/centers/program areas may participate (as suggested by the multiple CFDA numbers listed), the technology areas can span a broad range of biomedical, behavioral, and health-related inventions.

15) Which agency is offering this funding opportunity?

The agency is the National Institutes of Health (NIH).

16) What is the funding instrument type?

The funding instrument type is a grant.

17) What activity categories does this opportunity fall under?

The activity categories span education and health, consistent with NIH's biomedical and behavioral research mission.

18) What are the CFDA numbers associated with this opportunity, and what do they imply?

The information provided lists multiple CFDA numbers (including 93.121, 93.273, 93.279, 93.361, and several others). This typically implies that multiple NIH institutes, centers, or program areas may participate under this umbrella, and that relevant topics may be broad across NIH mission areas.

19) What is the Funding Opportunity Number (FOA number) for this announcement?

The Funding Opportunity Number provided is PA 18-705.

20) When was this FOA created, and what is the listed closing date?

The source data indicates the FOA was created on 2018-03-06 and lists an original closing date of 2021-09-05. Applicants may need to verify whether the opportunity is still active or has been superseded by a reissue or a newer announcement.

21) Why does the closing date matter for applicants?

Because the source data lists an original closing date of 2021-09-05, applicants should treat that as a signal to confirm the current status of the opportunity (active vs. expired vs. replaced). The information provided suggests it may have been superseded or reissued after that date.

22) What is the core "technology transfer" model described here?

NIH supplies the underlying intramural invention and provides a defined, research-focused patent license for the SBIR award period. The small business supplies the commercialization drive, development plan, and technical execution to advance the technology toward a product, with the constraint that the SBIR scope cannot include clinical trials under this FOA.